{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:32Z","timestamp":1793946512446,"version":"4.8.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105442","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:52:02Z","timestamp":1782229922000},"page":"105442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evolving treatment strategies in anal squamous cell carcinoma: Integrating chemoradiotherapy, immunotherapy, and emerging biomarkers"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6185-2336","authenticated-orcid":false,"given":"Francesco","family":"Di Costanzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evaristo","family":"Maiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana L.","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Trippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Di Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105442_bib1","first-page":"594","article-title":"RTOG 98-11 randomized trial","volume":"26","author":"Ajani","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105442_bib2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.6004\/jnccn.2023.0030","article-title":"NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma, Version 2. 2023","volume":"21","author":"Benson","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105442_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2013.05.037","article-title":"Faecal incontinence and quality of life after chemoradiotherapy for anal cancer","volume":"108","author":"Bentzen","year":"2013","journal-title":"Radiother. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105442_bib4","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105442_bib5","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/annonc\/mdw152","article-title":"Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes","volume":"27","author":"Chung","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105442_bib6","unstructured":"ClinicalTrials.gov. EA2165: Nivolumab plus carboplatin and paclitaxel in advanced anal cancer. NCT03233711. Available at: \u3008https:\/\/clinicaltrials.gov\/\u3009. Accessed March 15, 2026."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105442_bib7","first-page":"1379","article-title":"Safety and antitumor activity of retifanlimab in patients with previously treated advanced squamous carcinoma of the anal canal (POD1UM-202): a multicentre, open-label, phase 2 study","volume":"23","author":"Ott","year":"2022","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105442_bib8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cncr.20365","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"Daling","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105442_bib9","first-page":"135","article-title":"An updated review on imaging and staging of anal cancer\u2014Not just rectal cancer","volume":"9","author":"De Felice","year":"2023","journal-title":"Tomography"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105442_bib10","first-page":"1148","article-title":"Survivorship, quality of life, and late effects in cancer survivors: NCCN Guidelines Insights","volume":"20","author":"Denlinger","year":"2022","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105442_bib11","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","volume":"30","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105442_bib12","first-page":"861","article-title":"Systemic therapy for advanced anal carcinoma: current standards and future directions","volume":"17","author":"Eng","year":"2019","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.critrevonc.2026.105442_bib13","first-page":"246","article-title":"Management of residual disease after CRT for anal canal carcinoma","volume":"114","author":"Gerard","year":"2015","journal-title":"Radiother. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105442_bib14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(25)00213-X","article-title":"PLATO Trial Investigators. Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trial","volume":"26","author":"Gilbert","year":"2025","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105442_bib15","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.3390\/cancers13153895","article-title":"Present and Future Research on Anal Squamous Cell Carcinoma","volume":"13","author":"Spehner","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105442_bib16","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/0284186X.2018.1503713","article-title":"Late gastrointestinal toxicity after radiotherapy for anal cancer: a systematic literature review","volume":"57","author":"Pan","year":"2018","journal-title":"Acta Oncol."},{"key":"10.1016\/j.critrevonc.2026.105442_bib17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/bjc.2015.448","article-title":"Tumour-infiltrating lymphocytes and outcomes after CRT in anal cancer","volume":"114","author":"Gilbert","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105442_bib18","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Rao","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105442_bib19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(17)30071-2","article-title":"Timing of tumour regression after CRT (ACT II analysis)","volume":"18","author":"Glynne-Jones","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105442_bib20","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of RTOG 98-11","volume":"30","author":"Gunderson","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105442_bib21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"ACT II trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105442_bib22","first-page":"1941","article-title":"RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in anal canal cancer","volume":"31","author":"Kachnic","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105442_bib23","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105442_bib24","first-page":"279","article-title":"INTERACT-ION: induction ezabenlimab plus mDCF followed by chemoradiotherapy in locally advanced anal squamous cell carcinoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105442_bib25","first-page":"S224","article-title":"SCARCE (PRODIGE 60): atezolizumab plus modified docetaxel, cisplatin and fluorouracil (mDCF) in advanced squamous cell anal carcinoma","volume":"34","author":"Kim","year":"2023","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105442_bib26","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1245\/s10434-012-2485-1","article-title":"Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors for recurrence","volume":"19","author":"Lef\u00e8vre","year":"2012","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105442_bib27","first-page":"742","article-title":"Circulating HPV DNA as a biomarker in anal cancer: current evidence and clinical perspectives","volume":"14","author":"Lef\u00e8vre","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105442_bib28","article-title":"Avelumab with or without cetuximab in previously treated advanced anal cancer (CARACAS)","volume":"9","author":"Lonardi","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105442_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Pembrolizumab in advanced anal squamous cell carcinoma (KEYNOTE-158)","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"32","key":"10.1016\/j.critrevonc.2026.105442_bib30","first-page":"2827","article-title":"Combining immune checkpoint blockade with HPV-targeted vaccine (ISA101) in HPV-related cancers","volume":"37","author":"Massarelli","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105442_bib31","first-page":"31","article-title":"Chemoradiotherapy with or without panitumumab in locally advanced anal cancer (FFCD 0904)","volume":"145","author":"Meulendijks","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105442_bib32","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated metastatic anal cancer (NCI9673)","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105442_bib33","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: long-term results of the UKCCCR randomised trial","volume":"102","author":"Northover","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105442_bib34","first-page":"293","article-title":"HIV-specific differences in outcome of anal cancer treated with CRT","volume":"89","author":"Oehler-J\u00e4nne","year":"2008","journal-title":"Radiother. Oncol."},{"issue":"10495","key":"10.1016\/j.critrevonc.2026.105442_bib35","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(25)00631-2","article-title":"Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303\/InterAACT-2): a global, phase 3 randomised controlled trial","volume":"405","author":"Rao","year":"2025","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105442_bib36","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"InterAACT: cisplatin plus 5-FU versus carboplatin plus paclitaxel in advanced anal cancer","volume":"38","author":"Rao","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105442_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100529","article-title":"Retifanlimab in patients with squamous carcinoma of the anal canal who progressed following platinum-based chemotherapy (POD1UM-202)","volume":"7","author":"Rao","year":"2022","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105442_bib38","first-page":"277","article-title":"Systemic therapy in advanced anal squamous cell carcinoma","volume":"30","author":"Sclafani","year":"2018","journal-title":"Curr. Opin. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105442_bib39","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with HPV-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovi\u0107","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105442_bib40","first-page":"e17","article-title":"Long-term anorectal and sexual dysfunction after chemoradiotherapy for anal cancer","volume":"58","author":"Sunesen","year":"2015","journal-title":"Dis. Colon. Rectum"},{"issue":"33","key":"10.1016\/j.critrevonc.2026.105442_bib41","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations regarding HIV and cancer","volume":"35","author":"Uldrick","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105442_bib42","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Epidermoid anal cancer: results from a randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin","volume":"348","author":"UKCCCR Anal Cancer Trial Working Party","year":"1996","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105442_bib43","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1001\/jamaoncol.2023.4042","article-title":"Circulating tumor HPV DNA for surveillance of HPV-positive oropharyngeal squamous cell carcinoma: a narrative review","volume":"9","author":"Lang Kuhs","year":"2023","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105442_bib44","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/jamaoncol.2024.1821","article-title":"Assessing the evidence for circulating tumor HPV DNA in patients with oropharyngeal cancer","volume":"10","author":"Lee","year":"2024","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105442_bib45","first-page":"575","article-title":"Advances in systemic therapy for anal squamous cell carcinoma","volume":"19","author":"Eng","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600329X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600329X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:40:03Z","timestamp":1793943603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282600329X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":45,"alternative-id":["S104084282600329X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105442","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving treatment strategies in anal squamous cell carcinoma: Integrating chemoradiotherapy, immunotherapy, and emerging biomarkers","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105442"}}